Skip to main content
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED logo

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · MVP ISIN · AU000000MVP2 LEI · 9845007EAECAOD1U4493 ASX Manufacturing
Open in API
Filings indexed 907 across all filing types
Latest filing 2024-10-23 AGM Information
Country AU Australia
Listing ASX MVP

About MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

https://medicaldev.com

Medical Developments International Limited specializes in the development and distribution of emergency pain relief and respiratory products. The company's flagship product is Penthrox, a handheld, self-administered inhaler providing rapid-onset, non-opioid analgesia using methoxyflurane. Penthrox is utilized globally by emergency medical services, hospitals, and for procedural pain in various clinical settings. Additionally, the company manufactures a range of respiratory medical devices, including anti-static spacers and asthma management tools designed to optimize medication delivery. The organization focuses on providing portable, effective solutions for acute pain management and respiratory care, catering to healthcare professionals and patients in emergency, surgical, and primary care environments.

Recent filings

Filing Released Lang Actions
2024 Annual General Meeting Presentation 26 pages 4.4MB
AGM Information Classification · 95% confidence The document is a presentation related to the FY24 Annual General Meeting (AGM) of Medical Developments International Limited (MVP). It includes details such as the date of the AGM, instructions on how to ask questions and vote, summaries of resolutions proposed at the meeting, proxy results for each resolution, and information about the board and company performance highlights. The content is typical of materials shared during an AGM to inform shareholders and facilitate voting. There is no indication that this is a full annual report, earnings release, or other financial filing. The presence of voting results and resolutions further supports classification as AGM Information. The document length (over 14,000 characters) and detailed content confirm it is the presentation material itself, not just an announcement of the meeting or report publication.
2024-10-23 English
Results of 2024 Annual General Meeting 2 pages 600.8KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Results of Medical Development International Limited’s 2024 Annual General Meeting' and provides detailed voting results for resolutions passed at the AGM held on 24 October 2024. It references compliance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001, which pertain to disclosure of voting results. The content is focused on the official announcement of the voting outcomes rather than the AGM materials or the full annual report. The document length is short (3151 characters) and it explicitly states it is the results of the AGM voting. Therefore, this document is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-10-23 English
Notice of Initial Substantial Holder 2 pages 210.2KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 Notice of Initial Substantial Holder filed under the Corporations Act 2001. It details the acquisition of a substantial shareholding in Medical Developments (MVP) by Jencay Capital Pty Limited, including voting power percentages, number of shares acquired, dates of acquisition, and consideration paid. This type of filing is a notification of a major shareholding change, specifically the crossing of a substantial holding threshold. It is not a financial report, earnings release, or management report, nor is it an announcement of a meeting or voting results. The document fits the definition of a Major Shareholding Notification (MRQ). The document length and content confirm it is the actual notification, not just an announcement or certification. Therefore, the correct classification is MRQ with high confidence.
2024-10-23 English
Appendix 4C & Quarterly Activity Report - 30 September 2024 9 pages 375.2KB
Interim / Quarterly Report Classification · 100% confidence The document is titled as an ASX Announcement and contains a Quarterly Activity Report and Appendix 4C for Q1 FY25. It includes detailed financial updates such as revenue, cash flow from operating, investing, and financing activities, and outlook for the fiscal year. The presence of Appendix 4C, which is a quarterly cash flow report required by ASX Listing Rules, confirms this is a quarterly financial report. The document is comprehensive and contains substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. It is not merely an announcement of a report but the report itself with detailed financial statements and commentary. Therefore, the correct classification is Interim / Quarterly Report (IR). Q1 2025
2024-10-21 English
Notification of cessation of securities - MVP 4 pages 14.8KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the cessation of certain securities (performance rights) for Medical Developments International Limited. It includes specific information about the securities that have ceased, reasons for cessation, and updated issued capital figures. The document is a formal announcement related to changes in the company's issued capital securities, specifically the cessation of securities due to expiry or forfeiture. This type of announcement aligns with the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes such as cessation or expiry of securities. The document is relatively short (3772 characters) and is not a full financial report or regulatory filing but a specific capital change notification.
2024-10-01 English
Appendix 4G 13 pages 349.8KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a governance-related filing that provides a key to where corporate governance disclosures can be found, and confirms compliance with ASX Corporate Governance Council recommendations for the financial year ended 30 June 2024. The document explicitly states it is not a substitute for the corporate governance statement itself but serves as a verification tool. It does not contain financial statements or detailed financial performance data, nor is it a full annual report. It is a regulatory filing related to governance disclosures and compliance with listing rules. Given the content and purpose, this document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2024-09-19 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.